Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 12/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | ROS1 | P08922 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12264736 | 0.83 | DGAT1 (0.38) | CYP3A4CYP2D6OPRK1DGAT1FOLH1 | |
| SCHEMBL12264733 | 0.81 | EGFR (0.36) | CYP3A4CYP2D6OPRK1EGFRDGAT1 | |
| SCHEMBL12264731 | 0.78 | LMNA (0.41) | CYP3A4CYP2D6OPRK1EGFRJAK2 | |
| SCHEMBL27829237 | 0.77 | DRD2 (0.42) | EGFRGUSBFOLH1 | |
| SCHEMBL12264732 | 0.76 | LMNA (0.42) | CYP3A4CYP2D6OPRK1EGFRDGAT1 | |
| SCHEMBL941529 | 0.71 | LMNA (0.46) | CYP3A4CYP2D6OPRK1GUSBCYP19A1 | |
| SCHEMBL12427963 | 0.69 | TYMP (0.43) | CYP3A4CYP2D6OPRK1GUSBCYP19A1 | |
| SCHEMBL12427881 | 0.69 | TYMP (0.43) | CYP3A4CYP2D6OPRK1GUSBCYP19A1 | |
| SCHEMBL943184 | 0.69 | TYMP (0.43) | CYP3A4CYP2D6OPRK1GUSBCYP19A1 | |
| SCHEMBL941807 | 0.67 | MMP2 (0.43) | GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005972-A1 | Application of Staudinger Ligation in PET Imaging | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005972-A1 | Application of Staudinger Ligation in PET Imaging | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2011123444-A1 | APPLICATION OF STAUDINGER LIGATION IN PET IMAGING | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005972-A1 | Application of Staudinger Ligation in PET Imaging | SSTR4, TIE1, STAU1 | CYP3A4 2497/4885CYP2D6 4566/4885OPRK1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.